Navigation Links
New Study Results Published in the New England Journal of Medicine Show Dabigatran Etexilate Mesylate Reduces the Risk of Recurrent Venous Thromboembolism
Date:2/20/2013

ction to PRADAXA (e.g., anaphylactic reaction or anaphylactic shock)
  • A mechanical prosthetic heart valve 
  • WARNINGS & PRECAUTIONS 
    Risk of Bleeding

    PRADAXA increases the risk of bleeding and can cause significant and, sometimes, fatal bleeding. Promptly evaluate any signs or symptoms of blood loss (e.g., a drop in hemoglobin and/or hematocrit or hypotension). Discontinue PRADAXA in patients with active pathological bleeding.

    Risk factors for bleeding include concomitant use of medications that increase the risk of bleeding (e.g., anti-platelet agents, heparin, fibrinolytic therapy, and chronic use of NSAIDs). PRADAXA's anticoagulant activity and half-life are increased in patients with renal impairment. 

    A specific reversal agent for dabigatran is not available. Hemodialysis can remove dabigatran; however clinical experience for hemodialysis as a treatment for bleeding is limited. Activated prothrombin complex concentrates, recombinant Factor VIIa, or concentrates of factors II, IX or X may be considered but their use has not been evaluated. Protamine sulfate and vitamin K are not expected to affect dabigatran anticoagulant activity. Consider administration of platelet concentrates where thrombocytopenia is present or long-acting antiplatelet drugs have been used. 

    Thromboembolic and Bleeding Events in Patients with Prosthetic Heart Valves
    The safety and efficacy of PRADAXA in patients with bileaflet mechanical prosthetic heart valves (recently implanted or implanted more than 3 months prior to enrollment) was evaluated in the phase 2 RE-ALIGN trial. RE-ALIGN was terminated early because of significantly more thromboembolic events (valve thrombosis, stroke, transient ischemic attack, and myocardial infarction) and an excess of major bleeding (predominantly post-operative pericardial effusions requiring intervention for hemodynamic compromise) for PRADAXA vs warfarin. Therefore, the use
    '/>"/>

    SOURCE Boehringer Ingelheim Pharmaceuticals, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7

    Related medicine technology :

    1. Study Finds Utilizing Integrated Medical and Pharmacy Data Improves Ability to Forecast Use of High-cost Specialty Treatments
    2. Study Showed Patients Treated With The miraDry© System Experienced 82 Percent Sweat Reduction On Average
    3. Asubio Initiates Landmark Clinical Study in Spinal Cord Injury
    4. New Veridex Alliance Drives Study Of Circulating Tumor Cells In Men With Metastatic Prostate Cancer
    5. Shingles Vaccine is Safe, According to New Study
    6. Structural Trends to Profoundly Change Life Sciences Industry, Genpact Study Shows
    7. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
    8. Anthera Announces the Completion of Patient Dosing in Phase 2b PEARL-SC Study
    9. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
    10. Accuray Launches First Study to Compare CyberKnife® SBRT to Surgery and IMRT for Treatment of Early-Stage Prostate Cancer
    11. Interim results of VITOBA™ (VImpaT® added to One Baseline AED) Study Presented at the 64th Annual Meeting of the American Academy of Neurology
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:12/19/2014)... INC. (NYSE: RMD ) today announced that it ... on Thursday, January 22, 2015, after the New York Stock ... be issued after 1:00 p.m. US Pacific Time and the ... future outlook. The earnings call is scheduled to ... webcast of the call can be accessed on ResMed,s Investor ...
    (Date:12/19/2014)... 18, 2014   Aratana Therapeutics, Inc . ... focused on the licensing, development and commercialization of ... results from its pivotal field study of AT-001 ... in dogs with osteoarthritis.  In the study, dogs ... that were statistically significant compared to placebo (p<0.05) ...
    (Date:12/17/2014)... , Dec. 17, 2014 Royal Philips ... Corporation (NASDAQ: VOLC ), a global leader in ... that they have entered into a definitive merger agreement. Pursuant ... acquire all of the issued and outstanding shares of Volcano ... price of USD 1 billion (approx. EUR 800 million), to ...
    Breaking Medicine Technology:ResMed To Announce Second Quarter 2015 Results 2Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 2Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 3Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 4Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 5Philips to acquire Volcano to expand global leadership position in image-guided therapy market 2Philips to acquire Volcano to expand global leadership position in image-guided therapy market 3Philips to acquire Volcano to expand global leadership position in image-guided therapy market 4Philips to acquire Volcano to expand global leadership position in image-guided therapy market 5Philips to acquire Volcano to expand global leadership position in image-guided therapy market 6Philips to acquire Volcano to expand global leadership position in image-guided therapy market 7Philips to acquire Volcano to expand global leadership position in image-guided therapy market 8
    (Date:12/19/2014)... (HealthDay News) -- A new study suggests a possible ... hot flashes and night sweats -- and higher rates ... are common during menopause, affecting about 60 percent of ... after menopause, since they then face a higher risk ... women who exhibit moderate or severe menopausal symptoms are ...
    (Date:12/19/2014)... (HealthDay News) -- Traveling through the same U.S. airport ... three others within a four-hour time span, illustrating just ... shows. "The exposures in this report were not ... international terminal, highlighting the fact that measles is highly ... infectious disease specialist at the U.S. Centers for Disease ...
    (Date:12/17/2014)... December 17, 2014 Dr. Myo Nwe is ... Loss Diet of the Future” and co-founder of the Ace ... book, Dr. Nwe takes a broad look at the industry ... up under scientific scrutiny. On film and in television shows, ... mostly toward the social aspects and played for basic laughs, ...
    (Date:12/17/2014)... San Francisco, CA (PRWEB) December 17, 2014 ... the Stanford Center for Longevity, today, in reaction to a ... the emerging science of brain training and derogated the efficacy ... said that they agreed with the parts of the center’s ... however, they believed the center had also overstated its case, ...
    (Date:12/17/2014)... Project Veritas is releasing a video interview of ... and Obamacare architect Jonathan Gruber to public attention. Award-winning ... which is being distributed on YouTube. , During the ... the Affordable Care Act in order to hide a ... per year tax grab. , “President Obama promised us ...
    Breaking Medicine News(10 mins):Health News:Severe Hot Flashes During Menopause May Raise Hip Fracture Risk Later: Study 2Health News:Arriving Now at Gate 42: Measles 2Health News:Arriving Now at Gate 42: Measles 3Health News:Obesity Should Not Be a Hollywood Punchline, Weight Loss Doc Says 2Health News:Scientists to Stanford: Research Shows Brain Exercises Can Work 2Health News:Scientists to Stanford: Research Shows Brain Exercises Can Work 3Health News:Scientists to Stanford: Research Shows Brain Exercises Can Work 4Health News:Project Veritas: James O’Keefe Interviews the Man Who Discovered Jonathan Gruber Videos 2
    ... , MONDAY, Jan. 17 (HealthDay News) -- Heart ... to fare well in the long-run than patients whose depressive ... The research team from Duke University Medical Center said that ... Journal of the American College of Cardiology , is ...
    ... MONDAY, Jan. 17 (HealthDay News) -- Among long-term breast cancer ... to face much higher rates of death due to heart ... in the Jan. 25 issue of the Journal of ... breast cancer, such as that practiced until the mid-1980s, increased ...
    ... HealthDay Reporter , MONDAY, Jan. 17 (HealthDay News) -- ... flares of multiple sclerosis (MS), but does not help ... guidelines say. Plasma exchange, or plasmapheresis, is also ... chronic inflammatory demyelinating polyneuropathy and it may be considered ...
    ... in First Nations (North American Indian) babies are linked to ... from 4 weeks to 1 year of age), according to ... Association Journal ) (pre-embargo link only) http://www.cmaj.ca/embargo/cmaj100837.pdf . ... child being born above the 90th percentile relative to a ...
    ... HealthDay Reporter , MONDAY, Jan. 17 (HealthDay News) ... she was gravely wounded by an assassin,s bullet to her ... condition from critical to serious. Giffords underwent surgery Saturday ... since she was shot in the attack in Tucson that ...
    ... , MONDAY, Jan. 17 (HealthDay News) -- Older people ... channel blockers face an increased risk of developing dangerously ... they take certain antibiotics, Canadian researchers warn. "Two ... taking calcium channel blockers, can increase the risk substantially ...
    Cached Medicine News:Health News:Worsening Depression Adds to Heart Failure Risks: Study 2Health News:Breast Cancer Radiation Before 1984 Tied to Heart Disease 2Health News:Some Severe MS Flares Helped by Blood Filtering Treatment 2Health News:Some Severe MS Flares Helped by Blood Filtering Treatment 3Health News:High birth weight in First Nations babies linked to a higher risk of postneonatal death 2Health News:Rep. Giffords Continues to Improve 2Health News:Rep. Giffords Continues to Improve 3Health News:Some Antibiotics, Blood Pressure Meds a Bad Mix: Study 2Health News:Some Antibiotics, Blood Pressure Meds a Bad Mix: Study 3
    BD Vacutainer® PST™ Tubes contain spray-coated lithium heparin and a gel for plasma separation. They are used for plasma determinations in chemistry....
    MONOJECT Red/Yellow Mottled Stopper...
    BD Vacutainer® Specialty Tubes - Thrombin...
    BD Vacutainer® PST™ Tubes contain spray-coated lithium heparin and a gel for plasma separation. They are used for plasma determinations in chemistry....
    Medicine Products: